COMMUNIQUÉS West-GlobeNewswire

SkinHealth Systems Reports Second Quarter 2026 Financial Results
06/08/2026
LONG BEACH, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the second [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/08/2026
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
06/08/2026
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK ® ’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient [...]
Caring Brands Provides Intellectual Property Portfolio Update
06/08/2026
Commercial Patent Portfolio Includes Five Issued U.S. Patents Protecting Core Flagship Platforms Targeting $20B+ Combined Global Dermatology & Hair Care Markets Fort Pierce, FL, Aug. 06, 2026 (GLOBE NEWSWIRE) -- [...]
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
06/08/2026
Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned $1.0 billion to [...]
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
06/08/2026
Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
06/08/2026
PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the [...]
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
06/08/2026
First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual [...]
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
06/08/2026
Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of [...]
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
06/08/2026
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
06/08/2026
Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics [...]
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
06/08/2026
SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
06/08/2026
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented [...]
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
06/08/2026
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second [...]
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b [...]
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
06/08/2026
Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment Successful limited launch of the power liposuction handpiece for the AYON platform [...]
CVRx Reports Second Quarter 2026 Financial and Operating Results
06/08/2026
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Oculis Reports Q2 2026 Financial Results and Provides Company Update
06/08/2026
Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following [...]
Oculis Reports Q2 2026 Financial Results and Provides Company Update
06/08/2026
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential [...]

Pages